GlassScriptPhysician profile
James H Skorczewski
NPI 1487964813
$7,404.02
in general payments reported to CMS, 2019-2025
29 companies · $761 in 2025
The $761 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $719 · 2021: $1,303 · 2022: $2,122 · 2023: $814 · 2024: $598 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $839.75 | 2021-2025 | Indigo System, Penumbra System |
| Boston Scientific Corporation | $677.85 | 2019-2025 | Eluvia, Lux-Dx Insertable Cardiac Monitor |
| Inari Medical, INC. | $661.88 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $651.75 | 2019-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Philips North America LLC | $615.90 | 2021-2025 | Labosys, (Br5) Peripheral Ivus, (Bs1) Peripheral Vascular Undivided |
| Cardiovascular Systems INC. | $578.52 | 2019-2022 | |
| Abbott Laboratories | $517.46 | 2019-2025 | Diamondback Coronary, Esprit |
| Astrazeneca Pharmaceuticals LP | $497.82 | 2019-2022 | |
| Veryan Medical Incorporated | $384.20 | 2021-2022 | |
| Abiomed | $325.64 | 2022-2025 | |
| Medtronic, INC. | $315.97 | 2022-2025 | Spiderfx, Reveal Linq |
| Janssen Pharmaceuticals, INC | $234.25 | 2019-2020 | |
| Esperion Therapeutics, INC. | $147.64 | 2021 | |
| Ekos Corporation | $134.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.67 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $110.69 | 2023-2024 | R2p Misago |
| Endologix LLC | $98.71 | 2019 | |
| Acist Medical Systems, INC. | $97.22 | 2020 | |
| Angiodynamics, INC. | $76.78 | 2022 | |
| Medicure Pharma INC. | $74.05 | 2019 | |
| Pfizer INC. | $53.99 | 2019 | |
| Cardinal Health 200 LLC | $50.58 | 2020 | |
| Novartis Pharmaceuticals Corporation | $25.26 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.13 | 2019 | |
| Cordis US Corp. | $21.40 | 2022 | |
| Amgen INC. | $20.83 | 2025 | Repatha |
| Inspire Medical Systems, INC. | $19.71 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $19.32 | 2023 | |
| Bard Peripheral Vascular, INC. | $15.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Skorczewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.